Prognyx oncology intelligence

Live ClinicalTrials.gov oncology trial comparison around an asset, plus landscapes and CI briefings.

Should I use this

Quality & Safety

A
Description quality
100%
Schema completeness
97%
Naming quality
93%
Poisoning risk
100%
Permission match
100%
Protocol compliance
100%

Based on automated analysis of tool definitions and protocol compliance.

Context Cost

~568Tokens (tool definitions)
~951 BTypical response size
Minimal attention impact (0.44% of 128k context)

This is the approximate number of tokens consumed each time the server's tools are loaded into a model's context. Higher counts reduce the attention available for other tasks.

Install

One-Click Install

Add this to your `claude_desktop_config.json` file:

{
  "mcpServers": {
    "oncology-intelligence": {
      "url": "https://www.prognyx.com/api/mcp"
    }
  }
}

Remote endpoints

https://www.prognyx.com/api/mcpstreamable-http

What it can do

Tool inventory

Tools (3)

🟢 Read-only🟡 Write🔴 Delete⚪ Unknown
🟢compare_trials(asset, indication)

Up to three interventional ClinicalTrials.gov studies matching an asset or target AND an oncology indication, side by side: sponsor, phase, status, declared arms, primary outcomes, last update, registry URL. Active studies first, then later phase; different sponsors where possible. Use a target (e.g. "KIF18A", "B7-H3") rather than one drug name to see other programmes.

Input Schema

{
  "type": "object",
  "properties": {
    "asset": {
      "type": "string",
      "maxLength": 80,
      "description": "Public asset or target, e.g. \"sotorasib\", \"KRAS G12C\", \"B7-H3\"."
    },
    "indication": {
      "type": "string",
      "maxLength": 80,
      "description": "Oncology indication, e.g. \"colorectal cancer\", \"NSCLC\"."
    }
  },
  "required": [
    "asset",
    "indication"
  ],
  "additionalProperties": false
}
🟢search_registry(query, limit)

Live landscape for a target, asset, company, indication or NCT number: total and active study counts, leading sponsors, phase mix, the most recently updated studies with URLs, and related Prognyx briefings. Counts for phases and sponsors come from a recent sample, stated in the result.

Input Schema

{
  "type": "object",
  "properties": {
    "query": {
      "type": "string",
      "maxLength": 160,
      "description": "e.g. \"KRAS G12C\", \"Nuvalent\", \"claudin 18.2 gastric cancer\", \"NCT05132075\"."
    },
    "limit": {
      "type": "integer",
      "minimum": 1,
      "maximum": 25,
      "default": 10,
      "description": "Studies to return."
    }
  },
  "required": [
    "query"
  ],
  "additionalProperties": false
}
🟢search_briefings(query, limit)

Prognyx oncology competitive-intelligence briefings (each claim linked to a primary source) matching a drug, company, target or indication, newest first, with URL, date and summary.

Input Schema

{
  "type": "object",
  "properties": {
    "query": {
      "type": "string",
      "maxLength": 120,
      "description": "Drug, company, target or indication. Empty returns the latest."
    },
    "limit": {
      "type": "integer",
      "minimum": 1,
      "maximum": 20,
      "default": 5,
      "description": "Briefings to return."
    }
  },
  "additionalProperties": false
}

Community

Rate this Server

Evidence

Recent observations

verifiedversion not recorded3 tools